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Abstract 15 
 16 
Mutants with enhanced growth in the presence of an antibiotic are more difficult 17 
to identify than mutants where the antibiotic’s minimum inhibitory concentration 18 
increases, because they are not amenable to lethal selection in vitro. We report 19 
that activatory mutations in the CreC signal sensor enhance growth of Escherichia 20 
coli in the presence of cefoxitin, cefotaxime and meropenem without increasing 21 
their minimum inhibitory concentrations. Enhanced growth is dependent on over-22 
production of the inner-membrane cre-regulon protein CreD. 23 
24 
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Text 25 
In Escherichia coli, CreC is a sensor kinase and CreB is a response regulator and 26 
together they form a two-component regulatory system that controls the expression 27 
of the cre regulon, a group of genes with poorly characterised functions (1-3). We 28 
have previously shown that an activatory mutation in CreC in E. coli MG1655 confers 29 
the Cet phenotype: tolerance of the protein antibiotic Colicin E2, through over-30 
production of the protein YieI (3). Whilst the mechanism by which YieI confers colicin 31 
resistance is not clear it may be due to modifications in the outer envelope which 32 
restrict entry of colicin E2 to the cell (3). 33 
 34 
To learn more about the Cet phenotype, we used phenotype microarray analysis to 35 
characterise differences between CTX6, a well-characterised Cet mutant (3), versus 36 
CTX6ΔcreB, where cre regulon hyper-expression is ablated and the Cet phenotype is 37 
reversed (3). Phenotype microarray analysis was performed by BIolog (Hayward CA, 38 
USA). Of almost 2000 growth conditions tested in the phenotype microarray, 39 
significantly improved growth of CTX6 versus CTX6ΔcreB was seen in media with 13 40 
different chemical additions. Eight of these chemicals are β-lactam antibiotics (Table 41 
1). MICs of β-lactams were not noticeably higher against CTX6 than CTX6ΔcreB, 42 
according to E-test and broth microdilution methodologies (data not shown) but the 43 
CreC activatory mutation in CTX6 was reproducibly seen to enhance growth at sub-44 
MIC concentrations of some β-lactam drugs during growth curve analysis. For these 45 
assays, 500 µl of an overnight culture grown in LB medium (Oxoid) were used to 46 
inoculate 10 ml of fresh LB in a sealed universal bottle and the antimicrobial drug of 47 
interest was added. The starting optical density at 600 nm (OD600) of each subculture 48 
was approximately 0.1. Cultures were incubated at 37°C with 150 rpm shaking and 49 
OD600 measured every 60 min using a spectrophotometer by taking 1 ml from the 50 
culture. For example, E. coli MG1655 (the parent of CTX6) suffers a temporary 51 
slowing of growth at 120 min following addition of half the MIC of cefoxitin (Fig 1A) 52 
or cefotaxime (Fig 1B) (both from Sigma). Later, a post-antibiotic effect occurs, and 53 
growth of the population increases again (Fig. 1). CTX6 does not suffer such a 54 
prolonged slowing of growth after 120 min and there is a significant enhancement in 55 
OD600 at 180 or 360 min after the addition of cefoxitin or cefotaxime, respectively, 56 
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relative to MG1655 (p <0.05 for both). CTX6ΔcreB displays the wild-type phenotype 57 
(Fig. 1) confirming that CreBC hyper-activation is responsible for enhanced growth in 58 
the presence of these β-lactam antibiotics. 59 
 60 
Microarray transcriptomics has previously revealed that six genes are differentially 61 
regulated >10-fold in CTX6 in a CreB-dependent manner; none of these are known to 62 
be involve in β-lactam resistance or tolerance, e.g. porin, efflux pump, β-lactamase 63 
or penicillin binding protein genes (3). The use of previously constructed deletion 64 
mutants of the CreB-regulated genes in CTX6 (3) revealed that creD is gene 65 
responsible for enhanced growth of CTX6 in the presence of cefoxitin, as illustrated 66 
in figure 2. Deletion of creD in the CTX6 background reduced the OD600 of a culture 67 
at 180 min post addition of cefoxitin to the same extent as deletion of creB or creC 68 
(p<0.005 for each).  69 
 70 
It is possible to activate cre regulon gene expression by over-expressing the response 71 
regulator creB in an otherwise wild-type background strain. We did this, as 72 
previously, using an arabinose expression system (2) and found that it enhances 73 
growth in the presence of β-lactam antibiotics, even at antibiotic concentrations 74 
greater than the MIC. For example, with cefotaxime, the growth curve of MG1655 75 
carrying a control plasmid shows the drug inhibiting growth, lysing cells and 76 
overwhelming the population, causing the OD600 of the culture to reduce to basal 77 
levels (Fig. 3). Carriage of a plasmid allowing CreB over-production does not affect 78 
the MIC – the drug still kills the population – but the area under the growth curve is 79 
greater. There is more growth prior to killing, as seen particularly at 120 min post 80 
cefotaxime treatment in figure 3 (p<0.01). Deletion of creD blocks the ability of CreB 81 
over-production to improve the growth of MG1655 (p<0.05 at 120 min post 82 
cefotaxime treatment [Fig 3]) confirming a role for CreD over-production in this 83 
CreBC mediated β-lactam tolerance phenotype. 84 
 85 
To see if the β-lactam tolerant, CreC hyperactive mutant CTX6 gives a fitness 86 
advantage relative to CTX6ΔcreB over repeated cycles of growth, pairwise 87 
competition experiments were performed over 4 days. In order to mark CTX6ΔcreB 88 
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so that it could be quantified in a culture when mixed with CTX6, the derivative 89 
CTX6creB::ChlR was used. Here, creB has been disrupted by insertion of a 90 
chloramphenicol resistance gene rather than deleted as used in earlier experiments, 91 
though the effect on CreBC regulated gene expression is known to be identical 92 
whether creB is disrupted or deleted (2). CTX6yieJ::ChlR (3) was used in parallel as a 93 
control in these experiments to confirm that any change in fitness seen was specific 94 
to disruption of creB and not due to ChlR; yieJ is not responsible for the growth 95 
enhancement phenotype of CTX6 (Fig. 2). This control also allowed us to be sure that 96 
other, unrelated, mutations affecting growth in β-lactams did not readily accumulate 97 
in the E. coli strains used. 98 
 99 
To perform these pairwise competition experiments, initially, cultures of both strains 100 
to be competed were inoculated separately into LB and incubated for 24 h at 37°C 101 
with shaking at 160 rpm. Next, 5 µl of each culture were used to inoculate a separate 102 
flask containing 50 ml of DM25 minimal medium (4), which was prepared from Davis 103 
minimal medium (Difco, Oxford, UK) supplemented with glucose and thymine (25 104 
mg.l-1 and 2 mg.l-1 respectively). Cultures were incubated at 37°C with shaking as 105 
above. After overnight incubation, 500 µl of each culture was transferred into a fresh 106 
50 ml aliquot of DM25 minimal medium, again separately, and the inoculated 107 
medium was divided into six screw top universal bottles and incubated at 37°C 108 
overnight with shaking, as above. Upon inoculation, these cultures were referred to 109 
as day zero cultures. Day one (mixed) culture started with 250 µl each of the two day 110 
zero cultures to be competed being mixed together in the same flask containing 50 111 
ml of fresh DM25 medium plus a β-lactam antibiotic as necessary. There were six 112 
flasks (six biological replicates) for each competition experiment. The day one 113 
(mixed) cultures were incubated for 24 h (approximately 7 generations of growth are 114 
permitted given glucose limitation in the medium) at 37°C with shaking.  Each day, 115 
one culture was then sub-cultured by transferring a 500 µl of the culture into a 116 
separate flask containing 50 ml of DM25 medium (containing the same β-lactam, if 117 
necessary) to generate day two (mixed) cultures. The last step was repeated daily 118 
until four days of mixed cultures had passed. The competition between the two 119 
strains was measured by performing a serial dilution and counting the number of 120 
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colony forming units (cfu) per ml of CTX6 and of CTX6::ChlR in each mixture at the 121 
end of each day (including day zero). CTX6::ChlR was counted following plating on LB 122 
agar containing 30 mg.l-1 chloramphenicol. CTX6 was counted by plating on LB agar 123 
with no antibiotic and subtracting the CTX6::ChlR count. The selection rate constant 124 
(r) was used as a measure to estimate the fitness cost of ChlR insertion after each day 125 
of the competition by comparing M, the Malthusian parameter for each strain in the 126 
competition (5) so that M = ln(N1/N0), where N0 is the density of the strain (cfu/ml) 127 
at the start of the day (density at the end of the previous day divided by 100 to take 128 
account of the dilution factor on subculture) and N1 is the density of the strain 129 
(cfu/ml) at the end of the day. The selection rate for a competition is therefore 130 
calculated as r = M1-M2, Where M1 relates to CTX6 and M2 relates to CTX6::ChlR.  131 
For each competition (one mixed culture) there were four selection rate values, one 132 
for each day, and for each fitness cost experiment, six competitions were run. Hence 133 
for each competition between two strains, 24 r value datapoints are obtained.  134 
Differences in these sets of r value data for different comparisons were assessed 135 
using an unpaired t-test with Welch’s correction to assess the statistical significance 136 
of the differences observed. 137 
 138 
In the absence of antibiotics, neither CTX6creB::ChlR nor CTX6yieJ::ChlR had reduced 139 
fitness compared with the CreC hyper-active mutant CTX6 (Table 2). However, in the 140 
presence of half the MICs of cefotaxime, cefoxitin or meropenem (AdooQ 141 
Bioscience), an approximately 15% per day reduction in relative fitness (W) was 142 
observed for CTX6creB::ChlR versus CTX6 (p<0.05 for all comparisons) though there 143 
was no significant effect of disrupting yieJ (Table 2). We also performed competition 144 
experiments using ampicillin or ceftazidime (both from Sigma), but no significant 145 
difference in fitness between CTX6 and CTX6creB::ChlR was seen (Table 2). The 146 
reason for the specificity of this β-lactam tolerance effect is not clear but may 147 
facilitate future work to understand the mechanism of CreD mediated β-lactam 148 
tolerance in CTX6 and other CreC hyperactive mutants. To put the observed changes 149 
in relative fitness into perspective: starting with a ratio of approximately 1:1 for the 150 
two competing strains, after 4 days of competition the ratio was approximately 10:1 151 
in favour of CTX6 in the presence of half the MIC of cefoxitin, cefotaxime or 152 
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meropenem. MICs of meropenem were identical against five choramphenicol 153 
resistant and five susceptible colonies from the mixed culture of CTX6 and CTX6::ChlR 154 
at day zero, and after completion of the fitness cost experiment using meropenem. 155 
Accordingly, the observed relative increase in CTX6 population density over time is 156 
not caused by the accumulation of further mutations in CTX6 causing meropenem 157 
MIC to notably rise but instead is a phenotype caused by CreC hyper-active in E. coli 158 
MG1655. 159 
 160 
Conclusions 161 
Antibiotic resistance is defined in terms of a minimum inhibitory concentration (MIC) 162 
of an antibiotic measured following growth of a very dilute starting culture in the 163 
presence of that antibiotic. After a set period of incubation, the MIC is defined as the 164 
concentration of drug required to completely inhibit growth. If the MIC of a drug 165 
against a bacterial isolate is greater than a consensually defined breakpoint – based 166 
on clinical experience and pharmacokinentic/dynamic properties of the antibiotic – 167 
the isolate is said to be resistant (6). However, in vivo, antibiotic concentrations are 168 
dynamic, and there are periods when they are sub-MIC, so even susceptible bacteria 169 
can multiply before the drug concentration raises to overcome it. Whilst this does 170 
not, of itself, cause treatment failure, it might provide time for resistant mutants to 171 
emerge, or for symptoms to persist in the patient before a cure is established. 172 
Because of this possibility, we are interested in mutations that confer growth 173 
enhancement in the presence of an antibiotic without necessarily altering the 174 
antibiotic’s MIC. This phenotype of enhanced growth in the presence of antibiotic is 175 
somewhat different from the much-discussed phenotype of “persistence”, where 176 
bacteria reduce their metabolic activity and/or growth rate to escape from the lethal 177 
actions of antibiotics, which tend to only kill growing cells (7).  178 
 179 
In this paper, we have identified a mechanism – hyper-production of CreD due to 180 
constitutive activation of CreC by mutation – that confers growth enhancement in 181 
the presence of β-lactams in E. coli. The clinical relevance of this finding is unclear, 182 
and the mechanism by which CreD confers this phenotype is unknown. Interestingly, 183 
whilst CreC in E. coli is not activated by β-lactam challenge (1,2) CreBC shares 184 
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significant sequence identity with the BlrAB two-component system in Aeromonas 185 
spp (8,9), which is activated in response to β-lactam challenge, and controls β-186 
lactamase production and so confers β-lactam resistance (10). Importantly, BlrAB 187 
also activates transcription of blrD, which is a homologue of E. coli creD (9). Indeed, a 188 
similar two component system, CreBC/BlrAB in Pseudomonas aeruginosa is also 189 
activated during β-lactam challenge (11,12), and whilst it does not control β-190 
lactamase production, it does control transcription of the creD homologue in this 191 
species (11,12). Interestingly, CreD/BlrD hyper-production in P. aeruginosa does not 192 
enhance β-lactam MICs unless the chromosomally encoded AmpC cephalosporinase 193 
of this species is over-produced in parallel (12). It is possibility, therefore, that CreC 194 
hyper-activation leading to CreD hyper-production in E. coli might enhance β-lactam 195 
MICs in the presence of plasmid mediated β-lactamase(s), something that is worthy 196 
of future investigation.  197 
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Tables 255 
Table 1. Chemicals in Phenotype Microarray analysis where significant changes in 256 
growth – measured as an increased area under the growth curve (AUC) – were 257 
seen in CTX6 (Cet) versus CTX6ΔcreB. 258 
 259 
Moderate Effect 
(26-75% increase in AUC) 
Major Effect 
(>75% increase in AUC) 
Nafcillin Amoxicillin 
Ampicillin Cefotaxime 
Cefuroxime Aztreonam 
Cefoxitin Phenylarsine oxide 
Carbenicillin  
Cetylpyridinium chloride  
Thallium Acetate  
9-Aminoacridine  
Sodium Arsenate  
 260 
261 
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Table 2. Effect on fitness of disrupting creB in CTX6 measured in pairwise 262 
comparison with CTX6 during growth in the presence of half MIC of various 263 
antibiotics.  264 
Fitness was measured over four days, and is an average of six repetitions, as set out 265 
in the text. Data are mean percent fitness difference per day. Negative values mean 266 
that the ChlR derivative is less fit than CTX6 in pairwise competition. Stars represent 267 
differences where p<0.05 according to an unpaired t-test with Welch’s correction. 268 
 269 
 270 
Competition Relative Percent Fitness of ChlR strain 
CTX6creB:ChlR vs CTX6 
(No Antibiotic) 
+3.0 +/- 3.4 
CTX6yieJ:ChlR vs CTX6 
(No Antibiotic) 
-4.9 +/- 3.9 
CTX6creB:ChlR vs CTX6  
(Plus Ampicillin) 
+4.4 +/- 2.8 
CTX6creB:ChlR vs CTX6  
(Plus Ceftazidime) 
-0.7 +/- 4.8 
CTX6creB:ChlR vs CTX6  
(Plus Cefoxitin) 
-17.7 +/- 3.4* 
CTX6yieJ:ChlR vs CTX6  
(Plus Cefoxitin) 
-2.0 +/- 4.7 
CTX6creB:ChlR vs CTX6  
(Plus Cefotaxime) 
-12.4 +/- 4.9* 
CTX6creB:ChlR vs CTX6  
(Plus Meropenem) 
-15.9 +/- 4.1* 
271 
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Figure Legends 272 
 273 
Figure 1 Effect of Cet phenotype on E. coli growth curve in the presence of cefoxitin 274 
or cefotaxime. 275 
Optical density of an LB culture was measured at 600 nm every hour following 276 
subculture and addition of antibiotic (time zero): top graph, cefoxitin; bottom graph, 277 
cefotaxime, each used at half its MIC against E. coli MG1655. Data are mean 278 
plus/minus standard error of the mean, n=6 279 
 280 
 281 
Figure 2. Effect of deletion of various Cre regulon genes in the E. coli Cet mutant 282 
CTX6 on growth in the presence of cefoxitin. 283 
Optical density of an LB culture was measured at 600 nm every hour following 284 
subculture and addition of antibiotic (time zero). Data represent means plus/minus 285 
standard error of the mean, n=3 after 180 mins post incubation. 286 
 287 
 288 
Figure 3. Effect of activating the Cre regulon through over-production of CreB on E. 289 
coli growth in the presence of cefotaxime. 290 
Optical density of an LB culture was measured at 600 nm every hour following 291 
subculture and addition of cefotaxime (time zero) used at half its MIC against E. coli 292 
MG1655. Arabinose (0.2 % w/v) was added in all growth media to stimulate CreB 293 
production from the pUB6073 (pBAD(creB)) plasmid as used in (2). Data represent 294 
means plus/minus standard error of the mean, n=3 after 180 mins post incubation. 295 
 296 
 297 
 298 
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